|Mr. Scott Raymond Ward B.Sc., M.S., MS||Chairman, Pres & CEO||1.46M||N/A||1960|
|Mr. Jeffrey S. Points||Chief Financial Officer||682.69k||N/A||1977|
|Ms. Rhonda J. Robb||Chief Operating Officer||954.83k||N/A||1968|
|Mr. Alexander Rosenstein||Gen. Counsel & Corp. Sec.||614.96k||N/A||1972|
|Dr. Ryan D. Egeland M.D., Ph.D.||Chief Medical Officer||522.93k||N/A||1975|
|Mr. John M. Hastings||Exec. VP of Operations & Technology||N/A||N/A||1980|
|Mr. John E. Nielsen||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Sandra M. Sedo||Chief Compliance Officer||N/A||N/A||1964|
|Mr. David S. Whitescarver||VP of Corp. Devel. & Intellectual Property||N/A||N/A||1958|
|Mr. Stephen J. Rempe||Chief HR Officer||N/A||N/A||1973|
Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Cardiovascular Systems, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 10; Compensation: 2.